Share Price and Basic Stock Data
Last Updated: December 27, 2025, 11:21 pm
| PEG Ratio | -2.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Evoq Remedies Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹9.21 Cr and a share price of ₹3.70. The company reported sales of ₹20.39 Cr for the fiscal year ending March 2023, reflecting a growth trajectory from ₹16.78 Cr in March 2022. However, this growth is punctuated by a significant decline in the most recent quarter, with sales plummeting to ₹4.60 Cr in March 2023 and further down to ₹3.90 Cr in September 2023. Notably, the trailing twelve months (TTM) revenue stood at ₹37.27 Cr, indicating a potential recovery phase. Despite the recent downturn, Evoq’s historical sales figures suggest volatility, with peaks such as ₹15.79 Cr in September 2022 and a promising forecast of ₹25.51 Cr by September 2025. The company’s operational challenges are evident, as seen in the sharp sales fluctuations, which may affect investor confidence in the long term.
Profitability and Efficiency Metrics
Evoq Remedies reported a net profit of ₹1.76 Cr for the fiscal year ending March 2025, down from ₹1.62 Cr in March 2023. The company recorded an operating profit margin (OPM) of -3.72% in the most recent reporting period, indicating ongoing operational inefficiencies. This is in stark contrast to the OPM of 38.04% in March 2021, highlighting a significant decline in profitability. The return on equity (ROE) stood at 0.26%, while the return on capital employed (ROCE) was slightly higher at 0.35%, reflecting low efficiency in utilizing equity and capital. The cash conversion cycle (CCC) of 231.85 days further underscores the operational challenges, as it indicates prolonged periods for cash recovery from sales. These declining profitability metrics, combined with a negative operating profit in recent quarters, suggest that the company may need to reassess its operational strategies to regain profitability and efficiency.
Balance Sheet Strength and Financial Ratios
Evoq Remedies maintains a robust balance sheet with zero borrowings, reflecting a conservative financial strategy. The company’s reserves have increased to ₹19.69 Cr, indicating a solid capital base for future operations. The current ratio is exceptionally high at 9.10, suggesting ample liquidity to meet short-term obligations. However, the price-to-book value (P/BV) ratio stands at 0.14x, significantly lower than the typical sector range, indicating that the stock may be undervalued. The interest coverage ratio (ICR) is reported at 0.00x, which is concerning as it indicates the company does not generate enough earnings to cover any potential interest expenses, even though it currently carries no debt. The asset turnover ratio of 0.27% reflects underutilization of assets, suggesting that improvements in operational efficiency could enhance overall financial performance in the future.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Evoq Remedies illustrates a significant shift over recent periods. Promoter ownership has decreased from 73.53% in March 2022 to 11.21% by March 2025, while public shareholding has surged from 26.47% to 88.79% over the same period. This dramatic change reflects a transition towards a more publicly held company, potentially increasing liquidity but also raising concerns about promoter commitment. The number of shareholders rose to 1,679 by September 2025, indicating growing interest among retail investors. However, the declining promoter stake may lead to diminished confidence among investors regarding long-term strategic direction. The shift in shareholding dynamics calls for careful monitoring, as increased public ownership can lead to volatility in stock prices, particularly in response to operational challenges and profitability concerns.
Outlook, Risks, and Final Insight
The outlook for Evoq Remedies is mixed, with potential for recovery contingent on addressing operational inefficiencies and stabilizing revenue streams. The company faces risks such as fluctuating sales, declining profitability, and a highly negative operating profit margin. Additionally, the significant drop in promoter shareholding could impact investor sentiment and lead to volatility. On the positive side, the absence of debt, strong liquidity position, and increasing public interest may provide a foundation for recovery if operational improvements are realized. To navigate these challenges, Evoq may need to implement strategic initiatives aimed at enhancing operational efficiency and restoring profitability. If successful, the company could position itself for a more stable growth trajectory, though it must remain vigilant against the inherent risks of the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 4.93 | 11.85 | 15.79 | 4.60 | 3.90 | 0.15 | 0.00 | 11.76 | 25.51 |
| Expenses | 1.71 | 4.20 | 11.12 | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 | 26.46 |
| Operating Profit | 1.05 | 0.73 | 0.73 | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.60 | -0.95 |
| OPM % | 38.04% | 14.81% | 6.16% | 1.96% | -87.83% | 1.79% | -1,146.67% | -5.10% | -3.72% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 0.00 | 2.26 | 0.01 | 2.40 | 1.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Profit before tax | 1.05 | 0.73 | 0.73 | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 | 0.08 |
| Tax % | 22.86% | 0.00% | 50.68% | 0.00% | 33.84% | 28.57% | 29.63% | 0.00% | 2.27% | 25.00% |
| Net Profit | 0.81 | 0.73 | 0.36 | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 | 0.05 |
| EPS in Rs | 810.00 | 730.00 | 0.26 | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 | 0.02 |
Last Updated: December 27, 2025, 1:04 am
Below is a detailed analysis of the quarterly data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.51 Cr.. The value appears strong and on an upward trend. It has increased from 11.76 Cr. (Mar 2025) to 25.51 Cr., marking an increase of 13.75 Cr..
- For Expenses, as of Sep 2025, the value is 26.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.36 Cr. (Mar 2025) to 26.46 Cr., marking an increase of 14.10 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.95 Cr.. The value appears to be declining and may need further review. It has decreased from -0.60 Cr. (Mar 2025) to -0.95 Cr., marking a decrease of 0.35 Cr..
- For OPM %, as of Sep 2025, the value is -3.72%. The value appears strong and on an upward trend. It has increased from -5.10% (Mar 2025) to -3.72%, marking an increase of 1.38%.
- For Other Income, as of Sep 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 2.40 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 1.34 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.04 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 1.76 Cr. (Mar 2025) to 0.08 Cr., marking a decrease of 1.68 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 2.27% (Mar 2025) to 25.00%, marking an increase of 22.73%.
- For Net Profit, as of Sep 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 1.71 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 1.66 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.69 (Mar 2025) to 0.02, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:23 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 37.27 |
| Expenses | 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | 38.82 |
| Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.55 |
| OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% | -4.16% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 | 3.46 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.07 |
| Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 | 1.84 |
| Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | ||
| Net Profit | 0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | 1.76 |
| EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 | 0.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | 51.39% | 48.62% | -72.22% | -80.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 151.39% | -2.77% | -120.85% | -7.78% |
Evoq Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -11% |
| TTM: | 190% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -56% |
| TTM: | -80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -43% |
| 1 Year: | -60% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:51 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 | 24.90 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.69 |
| Borrowings | 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | 0.00 |
| Other Liabilities | 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | 7.63 |
| Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | 0.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 52.02 |
| Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
Below is a detailed analysis of the balance sheet data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.90 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.90 Cr..
- For Reserves, as of Sep 2025, the value is 19.69 Cr.. The value appears strong and on an upward trend. It has increased from 19.64 Cr. (Mar 2025) to 19.69 Cr., marking an increase of 0.05 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.47 Cr. (Mar 2025) to 7.63 Cr., marking an increase of 2.16 Cr..
- For Total Liabilities, as of Sep 2025, the value is 52.22 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.22 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.02 Cr.. The value appears strong and on an upward trend. It has increased from 49.79 Cr. (Mar 2025) to 52.02 Cr., marking an increase of 2.23 Cr..
- For Total Assets, as of Sep 2025, the value is 52.22 Cr.. The value appears strong and on an upward trend. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
Notably, the Reserves (19.69 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.02 | -0.01 | 0.95 | -6.70 | -13.31 | -5.88 | -2.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 |
| Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 |
| Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 |
| Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 |
| Working Capital Days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 |
| ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Diluted EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Cash EPS (Rs.) | 0.05 | 0.33 | 1.19 | 0.80 | 713.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Revenue From Operations / Share (Rs.) | 4.72 | 2.98 | 14.99 | 12.34 | 10024.80 |
| PBDIT / Share (Rs.) | 0.07 | 0.45 | 1.68 | 1.08 | 953.90 |
| PBIT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.08 | 953.90 |
| PBT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.07 | 953.90 |
| Net Profit / Share (Rs.) | 0.03 | 0.33 | 1.19 | 0.80 | 713.80 |
| PBDIT Margin (%) | 1.50 | 15.26 | 11.22 | 8.71 | 9.51 |
| PBIT Margin (%) | 1.09 | 15.08 | 11.21 | 8.71 | 9.51 |
| PBT Margin (%) | 1.09 | 15.08 | 11.20 | 8.68 | 9.51 |
| Net Profit Margin (%) | 0.75 | 11.16 | 7.94 | 6.50 | 7.12 |
| Return on Networth / Equity (%) | 0.19 | 1.79 | 6.53 | 4.71 | 96.93 |
| Return on Capital Employeed (%) | 0.28 | 2.42 | 9.22 | 6.31 | 128.45 |
| Return On Assets (%) | 0.17 | 1.22 | 4.64 | 3.27 | 8.87 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.38 | 0.35 | 0.01 |
| Asset Turnover Ratio (%) | 0.27 | 0.11 | 0.59 | 0.81 | 1.46 |
| Current Ratio (X) | 9.10 | 3.17 | 3.45 | 3.28 | 1.10 |
| Quick Ratio (X) | 8.69 | 2.90 | 3.25 | 3.20 | 1.08 |
| Inventory Turnover Ratio (X) | 4.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 1761.31 | 316.78 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 1246.62 | 237.30 | 0.00 |
| Enterprise Value (Cr.) | 6.16 | 15.91 | 27.09 | 35.80 | 0.00 |
| EV / Net Operating Revenue (X) | 0.52 | 3.92 | 1.33 | 2.13 | 0.00 |
| EV / EBITDA (X) | 34.78 | 25.71 | 11.83 | 24.47 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| Price / BV (X) | 0.14 | 0.46 | 0.71 | 1.33 | 0.00 |
| Price / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| EarningsYield | 0.01 | 0.03 | 0.09 | 0.03 | 0.00 |
After reviewing the key financial ratios for Evoq Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 0.33 (Mar 24) to 0.05, marking a decrease of 0.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.72. It has increased from 2.98 (Mar 24) to 4.72, marking an increase of 1.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.07, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.33 (Mar 24) to 0.03, marking a decrease of 0.30.
- For PBDIT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has decreased from 15.26 (Mar 24) to 1.50, marking a decrease of 13.76.
- For PBIT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For PBT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For Net Profit Margin (%), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 5. It has decreased from 11.16 (Mar 24) to 0.75, marking a decrease of 10.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 15. It has decreased from 1.79 (Mar 24) to 0.19, marking a decrease of 1.60.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 10. It has decreased from 2.42 (Mar 24) to 0.28, marking a decrease of 2.14.
- For Return On Assets (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 1.22 (Mar 24) to 0.17, marking a decrease of 1.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. It has increased from 0.11 (Mar 24) to 0.27, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 9.10. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 9.10, marking an increase of 5.93.
- For Quick Ratio (X), as of Mar 25, the value is 8.69. This value exceeds the healthy maximum of 2. It has increased from 2.90 (Mar 24) to 8.69, marking an increase of 5.79.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 4.40, marking an increase of 4.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.16. It has decreased from 15.91 (Mar 24) to 6.16, marking a decrease of 9.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 3.92 (Mar 24) to 0.52, marking a decrease of 3.40.
- For EV / EBITDA (X), as of Mar 25, the value is 34.78. This value exceeds the healthy maximum of 15. It has increased from 25.71 (Mar 24) to 34.78, marking an increase of 9.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For Price / BV (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.14, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Evoq Remedies Ltd:
- Net Profit Margin: 0.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.28% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 8.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 5.23 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1106, Empire Business Hub, Ahmedabad Gujarat 380060 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhumishth Patel | Managing Director |
| Mr. Narendrakumar Patel | Non Executive Director |
| Mr. Harsh Kothari | Independent Director |
| Ms. Pushpa Joshi | Independent Director |
FAQ
What is the intrinsic value of Evoq Remedies Ltd?
Evoq Remedies Ltd's intrinsic value (as of 28 December 2025) is 0.20 which is 94.59% lower the current market price of 3.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9.21 Cr. market cap, FY2025-2026 high/low of 8.28/2.11, reserves of ₹19.69 Cr, and liabilities of 52.22 Cr.
What is the Market Cap of Evoq Remedies Ltd?
The Market Cap of Evoq Remedies Ltd is 9.21 Cr..
What is the current Stock Price of Evoq Remedies Ltd as on 28 December 2025?
The current stock price of Evoq Remedies Ltd as on 28 December 2025 is 3.70.
What is the High / Low of Evoq Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Evoq Remedies Ltd stocks is 8.28/2.11.
What is the Stock P/E of Evoq Remedies Ltd?
The Stock P/E of Evoq Remedies Ltd is 5.23.
What is the Book Value of Evoq Remedies Ltd?
The Book Value of Evoq Remedies Ltd is 17.9.
What is the Dividend Yield of Evoq Remedies Ltd?
The Dividend Yield of Evoq Remedies Ltd is 0.00 %.
What is the ROCE of Evoq Remedies Ltd?
The ROCE of Evoq Remedies Ltd is 0.35 %.
What is the ROE of Evoq Remedies Ltd?
The ROE of Evoq Remedies Ltd is 0.26 %.
What is the Face Value of Evoq Remedies Ltd?
The Face Value of Evoq Remedies Ltd is 10.0.